Literature DB >> 2176676

Colocalization of neurotensin receptors and of the neurotensin-degrading enzyme endopeptidase 24-16 in primary cultures of neurons.

J Chabry1, F Checler, J P Vincent, J Mazella.   

Abstract

This paper compares the localization of neurotensin receptors and of endopeptidase 24-16, a peptidase likely involved in the inactivation of neurotensin in primary cultures of neurons. Neurotensin binding sites were radiolabeled with 125I-Tyr3-neurotensin, whereas endopeptidase 24-16 was stained by immunohistochemical techniques using a monospecific polyclonal antibody. Endopeptidase 24-16 is present in 80-85% of the nondifferentiated neurons. The proportion of immunoreactive neurons decreased during maturation to reach 35-40% after 4-8 d of culture. By contrast, neurotensin receptors were not detectable in nondifferentiated cells and appear during maturation. Specific 125I-Tyr3-neurotensin labeling is maximal after 4 d of culture and is located on about 10% of differentiated neurons. Double-labeling experiments show that about 90% of cortical, hypothalamic, and mesencephalic neurons bearing the neurotensin receptor also contained endopeptidase 24-16, supporting the hypothesis that one of the functions of endopeptidase 24-16 is the physiological inactivation of neurotensin. However, the presence of endopeptidase 24-16 on numerous neurons that do not contain neurotensin receptors also suggests that the enzyme could be involved in the degradation and/or maturation of other neuropeptides.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2176676      PMCID: PMC6570059     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  10 in total

1.  Structure of neurolysin reveals a deep channel that limits substrate access.

Authors:  C K Brown; K Madauss; W Lian; M R Beck; W D Tolbert; D W Rodgers
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-06       Impact factor: 11.205

Review 2.  Adipokinetic hormones: cell and molecular biology.

Authors:  M O'Shea; R C Rayne
Journal:  Experientia       Date:  1992-05-15

3.  Fluorimetric assay of the neurotensin-degrading metalloendopeptidase, endopeptidase 24.16.

Authors:  P Dauch; H Barelli; J P Vincent; F Checler
Journal:  Biochem J       Date:  1991-12-01       Impact factor: 3.857

4.  Distinct properties of neuronal and astrocytic endopeptidase 3.4.24.16: a study on differentiation, subcellular distribution, and secretion processes.

Authors:  B Vincent; A Beaudet; P Dauch; J P Vincent; F Checler
Journal:  J Neurosci       Date:  1996-08-15       Impact factor: 6.167

5.  Differential binding profile and internalization process of neurotensin via neuronal and glial receptors.

Authors:  D Nouel; M P Faure; J A St Pierre; R Alonso; R Quirion; A Beaudet
Journal:  J Neurosci       Date:  1997-03-01       Impact factor: 6.167

6.  Characterization of high affinity neurotensin receptor NTR1 in HL-60 cells and its down regulation during granulocytic differentiation.

Authors:  S Y Choi; H D Chae; T J Park; H Ha; K T Kim
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

Review 7.  Neurolysin: From Initial Detection to Latest Advances.

Authors:  Frédéric Checler; Emer S Ferro
Journal:  Neurochem Res       Date:  2018-08-29       Impact factor: 3.996

8.  In vivo and in vitro neurotoxicity of the human prion protein (PrP) fragment P118-135 independently of PrP expression.

Authors:  Joëlle Chabry; Christiane Ratsimanohatra; Isabelle Sponne; Pierre-Paul Elena; Jean-Pierre Vincent; Thierry Pillot
Journal:  J Neurosci       Date:  2003-01-15       Impact factor: 6.167

9.  Potent inhibition of endopeptidase 24.16 and endopeptidase 24.15 by the phosphonamide peptide N-(phenylethylphosphonyl)-Gly-L-Pro-L-aminohexanoic acid.

Authors:  H Barelli; V Dive; A Yiotakis; J P Vincent; F Checler
Journal:  Biochem J       Date:  1992-10-15       Impact factor: 3.857

10.  Phosphorus-containing peptides as mixed inhibitors of endopeptidase 3.4.24.15 and 3.4.24.16: effect on neurotensin degradation in vitro and in vivo.

Authors:  B Vincent; V Dive; A Yiotakis; C Smadja; R Maldonado; J P Vincent; F Checler
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.